Timing of Tyrosine Kinase Inhibitor Switching in Chronic Myeloid Leukemia: A Comparative Analysis of Early Versus Late Strategies
Chidiebube J. Ugwu(Jefferson Hospital), Alankrita Taneja(Sidney Kimmel Cancer Center), Muluken Megiso(Jefferson Hospital), Elvis Obomanu(Jefferson Einstein Philadelphia Hospital), Nneoma Ubah(Montefiore Medical Center), Angimar Uriepero-Palma(Jefferson Hospital), Gàbor Varadi(Hadassah Academic College), Folajimi Atunde(Sinai Hospital), Ana Chachua(Jefferson Hospital), Sam King(Jefferson Hospital), Colton Jones(The University of Texas at San Antonio Health Science Center), Tarfa Verinumbe(Albert Einstein College of Medicine)
Cited by 0
Related Papers
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis
|Experimental Hematology|2000|111